Enzo Biochem announces initiatives designed to accelerate growth
Enzo Biochem announced several initiatives in its labs business unit designed to propel and accelerate growth. The initiatives are part of a company-wide commitment to expand its market opportunity in diagnostic testing, capitalizing on Enzo's innovation, differentiated business strategy and emerging market dynamics. Enzo recently won New York State Health Department approval for use of its AmpiProbe(R) Neisseria gonorrhoeae, or NG, and Chlamydia trachomatis, or CT, DNA tests with oral and rectal specimens. This expands Enzo's menu, allowing the company to provide for STI testing for not only women but also men, who represent a growing segment for such testing. Enzo is rolling out a new lab-to-labs business model. With it, Enzo will serve as the "central capability" for smaller labs. Enzo is expanding its service offerings to clinical research organizations, or CROs, academic research institutions and the pharmaceutical industry. Over the next few months, Enzo plans to extend these services to a broader array of customers.